Bone Biologics Corp
bonebiologics.comWhat Do They Do?
Develops a bone-graft device combining a bone-growth protein with processed bone matrix for spine surgeons treating patients undergoing lumbar spinal fusion.
10-K for FY2025, filed Mar 2, 2026We are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known…View ↗
Our lead product candidate is expected to be purified NELL-1 mixed with 510(k)-cleared DBM Demineralized Bone Putty recommended for use in…View ↗
DBM Putty is a matrix composed of processed human cortical bone. Demineralized bone granules are mixed with sodium hyaluronate to form the…View ↗
The populations of interest include spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine, for…View ↗
How Do They Make Money?
$1.1B
-
10-K for FY2020, filed Apr 15, 2021
$1.1B ↗
Who Are Their Customers?
Spine surgeons and patients with a skeletal bone defect or bone-related spinal condition are the relevant groups; other biologics can help patients avoid a second operation to harvest hip bone for fusion.
10-K for FY2025, filed Mar 2, 2026The populations of interest include spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine, for…View ↗
Do Revenues Turn Into Profits?
No. It lost $1.8M in FY2020.
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Oct 26, 2026
−$617.7KView ↗
- ▼ −7% (Loss)
- vs −$666.7K in Q3 FY2025
-
Sep 10, 2026
Nasdaq notified Bone Biologics of a minimum-bid-price deficiency
The company has until March 9, 2027, to regain compliance; the notification has no immediate effect on its Nasdaq listing.
Sources
8-K, filed Sep 16, 2026
Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until March 9, 2027, in which to regain compliance…View ↗
Flat. Revenue was $1.1B in FY2020, about the same as the $1.1B of FY2019.
Who Do They Compete With?
Competes with Medtronic, Stryker, Globus Medical, and DePuy-Synthes
10-K for FY2025, filed Mar 2, 2026Our business is in a very competitive and evolving field, that faces competition from large established orthopedic companies such as (but…View ↗
Loading...
